

Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com December 5th

December 2, 2013 4:07 PM ET

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference

NEW YORK, Dec. 2, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) the San Diego-based regenerative medicine company focused on using its breakthrough NovoGen 3D human tissue printing technology to create tissue on demand for medical research and therapeutic applications, today announced that Keith Murphy, CEO, will present at RetailInvestorConferences.com.

DATE: December 5, 2013

TIME: 12:30 PM EST

LINK: www.retailinvestorconferences.com > click on the red "register / watch event now" button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

The Company also [recently reported](#) Q2 fiscal 2014 results and provided business update

Recent Corporate Highlights

- Achieved greater than one month performance and drug responsiveness for 3D bioprinted liver tissues
- Listed common stock on the NYSE MKT, began trading on July 11th
- Successfully completed a \$46.6 million public offering on August 7th
- Elected Ms. Howson and Dr. Heyman to the Company's Board of Directors
- Organovo and Methuselah Foundation announced funding of bioprinting research at research institutions
- Organovo entered into new agreements with strategic partners to expand the use of our 3D tissues
- Appointed Continental Stock Transfer & Trust as our transfer agent and registrar

About Organovo Holdings, Inc.:

Organovo (NYSE MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Sign up for [email updates](#) and connect with us on [Twitter](#) (@Organovo).

About RetailInvestorConferences.com:

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our report on Form 10-Q filed August 9, 2013, the prospectus supplement filed with the SEC on August 2, 2013 and the transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

SOURCE Organovo Holdings, Inc.

Organovo, Investors: Barry Michaels, Chief Financial Officer, 1-858-224-1003, IR@organovo.com, or Gerry Amato, Booke & Company Investor Relations, admin@bookeandco.com; or RetailInvestorConferences.com, Bradley H. Smith, bradley.smith@prnewswire.com, 1.201.942.7157